Youssef, Michael
Ludmir, Ethan B.
Mandel, Jacob J.
Patel, Akash J.
Jalali, Ali
Treiber, Jeffrey
Wu, Jimin
McAleer, Mary Frances
de Groot, John F. http://orcid.org/0000-0003-1454-6461
Article History
Received: 31 July 2019
Accepted: 27 September 2019
First Online: 23 October 2019
Compliance with ethical standards
:
: Dr. John de Groot—Grant or Research Support: Sanofi-Aventis, Astrazeneca, EMD-Serono; Eli Lilly, Novartis, Deciphera Pharmaceuticals, Mundipharma; Paid Consultant: Celldex; Deciphera Pharmaceuticals, AbbVie, FivePrime Therapeutics, Inc., GW Pharma, Carthera, Eli Lilly, Boston Biomedical Inc.,Taiho Pharmaceuticals, Kairos Venture Investments, Syneos Health, Monteris, Agios, Mundipharma, Blue Earth Diagnostics; Advisory Boards: Genentech, Celldex, Foundation Medicine, Inc., Novogen, Deciphera, Astrazeneca, Insys Therapeutics, Kadmon, Merck, Eli Lilly, Novella Clinical, Blue Earth Diagnostics; Other Relevant Financial or Material Interests: DSMB: VBL Therapeutics; DSMB: Novella; VBI Vaccines, Inc.; Stock Ownership: Ziopharm Oncology, Gilead; Company Employment (Spouse): Ziopharm Oncology. None of the other authors have any conflict of interests to report.
: This article does not contain any studies with human participants or animals performed by any of the authors and was a retrospective study performed with approval of the IRB of the respective institutions.